Quick Answer
Selenium Sleep Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Previous treatments did not result in significant improvement of clinical symptoms.
Key Takeaways
- 01Previous treatments did not result in significant improvement of clinical symptoms. [Burgard Harald (2026)]
- 02Results showed increased values for LDL cholesterol (131 mg/dl), total cholesterol (219 mg/dl) while malondialdehyde-modified (MDA)-LDL a marker for fat oxidation was in the upper normal range (71 U/l), increased RANTES (Regulated And Normal T cell Expressed and Secreted) a marker for dental foci (58.4 ng/mL) and leaky gut with increased zonuline (48 ng/mL). [Burgard Harald (2026)]
- 03Excess immunoglobulin was found for laboratory allergy marker IgE (350 kU/l), while the antioxidative thiol status was decreased. [Burgard Harald (2026)]
- 04Based on recent studies, a potential role of the gut–brain axis in Parkinson’s disease can be supported. [Burgard Harald (2026)]
The current Migaku evidence database contains 2 reusable source documents for Selenium Sleep Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts.
- Previous treatments did not result in significant improvement of clinical symptoms. [Burgard Harald (2026); evidence level 4]
- Results showed increased values for LDL cholesterol (131 mg/dl), total cholesterol (219 mg/dl) while malondialdehyde-modified (MDA)-LDL a marker for fat oxidation was in the upper normal range (71 U/l), increased RANTES (Regulated And Normal T cell Expressed and Secreted) a marker for dental foci (58.4 ng/mL) and leaky gut with increased zonuline (48 ng/mL). [Burgard Harald (2026); evidence level 4]
- Excess immunoglobulin was found for laboratory allergy marker IgE (350 kU/l), while the antioxidative thiol status was decreased. [Burgard Harald (2026); evidence level 4]
- Based on recent studies, a potential role of the gut–brain axis in Parkinson’s disease can be supported. [Burgard Harald (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources